Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT04830046
Official study title

Covid-19 Vaccine Responsiveness in MM and Waldenstrom

Study summary

This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forMultiple Myeloma · Waldenstrom Macroglobulinemia

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 26, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?Massachusetts General Hospital

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Massachusetts General Hospital
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Age \>18 years.
  • Lack of a contra-indication to a currently available COVID-19 vaccine.
  • Diagnosis of MM according to International Myeloma Working Group (IWMG) criteria (Cohort 1) or Diagnosis of WM according to WHO criteria (Cohort 2)
  • For treatment naïve WM patients (Cohort 2A):
  • Patient must have no prior history of anticancer treatment for WM.
  • The treating investigator must have no intention to initiate WM therapy within 2 months
  • For WM patients receiving BTK inhibitor (Cohort 2B):
  • Patient must have no history of cytotoxic chemotherapy within 1 year, and no history of other anticancer therapy within 6 months.
  • For currently or previously treated WM patients (Cohort 2C):
  • Patient must not be currently taking a BTK inhibitor or had recent exposure within 1 month of enrollment. Current or prior history of any other WM-directed therapy is allowed.
Reasons someone may not be able to joinExclusion criteria

\-

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Brigham and Women's HospitalBoston, Massachusetts
  • Dana-Farber Cancer InstituteBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 26, 2025. Always confirm current availability with the study team.

View original record ↗